{"id":1957,"date":"2020-02-21T19:25:02","date_gmt":"2020-02-22T00:25:02","guid":{"rendered":"https:\/\/bridgebioprod.wpengine.com\/?p=1957"},"modified":"2022-06-22T16:01:03","modified_gmt":"2022-06-22T20:01:03","slug":"bridgebio-pharma-and-eidos-therapeutics-to-present-at-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-and-eidos-therapeutics-to-present-at-upcoming-investor-conferences\/","title":{"rendered":"BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences"},"content":{"rendered":"\r\n<p>PALO ALTO, Calif., February 21, 2020 \u2013 BridgeBio Pharma, Inc. (Nasdaq: BBIO), together with affiliate company Eidos Therapeutics (Nasdaq: EIDX) announced today that they are presenting at two upcoming investor conferences:<\/p>\r\n\r\n\r\n\r\n<ul class=\"wp-block-list\">\r\n<li>The SVB Leerink Annual Global Healthcare Conference on Tuesday, February 25, 2020 at 1PM (EST) in New York.<\/li>\r\n<li>The Cowen and Company Annual Health Care Conference on Wednesday, March 4, 2020 at 9:20AM (EST) in Boston.<\/li>\r\n<\/ul>\r\n\r\n\r\n\r\n<p>The presentations will be webcast live and can be accessed at\u00a0<a href=\"http:\/\/bridgebio.com\/\"><strong>www.bridgebiodev.wpengine.com<\/strong><\/a>\u00a0on the\u00a0<em>For Investors<\/em>\u00a0page under\u00a0<em>News &amp; Events.<\/em>\u00a0The webcast will be available for replay for 30 days.<\/p>\r\n\r\n\r\n\r\n<p><strong>About BridgeBio Pharma<\/strong><\/p>\r\n\r\n\r\n\r\n<p>BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio\u2019s pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development. For more information, visit\u00a0<a href=\"http:\/\/bridgebio.com\/\">bridgebiodev.wpengine.com<\/a>.<\/p>\r\n\r\n\r\n\r\n<p><strong>About Eidos Therapeutics<\/strong><\/p>\r\n\r\n\r\n\r\n<p>Eidos is a BridgeBio Pharma affiliate company focused on addressing the large and growing unmet need caused by transthyretin (TTR) amyloidosis (ATTR). Eidos is developing AG10, a potentially disease-modifying therapy for the treatment of ATTR. For more information, please visit www.eidostx.com.<\/p>\r\n\r\n\r\n\r\n<p>Media contact: <br \/>BridgeBio Pharma, Inc. <br \/>Grace Rauh <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EWYCdvqfLyG_K0QTU2AJ2sVtp8YY-vj_5HmQai_GaHEwIGjMDu5y6Rtb4hDeKquHMN06Th-qe0lIbxII6KhoNzkfAWEaTG27GijiYWds_QM=\" target=\"_blank\" rel=\"noreferrer noopener\">Grace.rauh@bridgebiodev.wpengine.com<\/a><br \/>(917) 232-5478<\/p>\r\n\r\n\r\n\r\n<p>Investor contact: <br \/>John Grimaldi, Burns McClellan <br \/><a href=\"mailto:jgrimaldi@burnsmc.com\"><strong>jgrimaldi@burnsmc.comj<\/strong><\/a><br \/>212-213-0006 x362<\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>PALO ALTO, Calif., February 21, 2020 \u2013 BridgeBio Pharma, Inc. (Nasdaq: BBIO), together with affiliate company Eidos Therapeutics (Nasdaq: EIDX) announced today that they are presenting at two upcoming investor conferences: The SVB Leerink Annual Global Healthcare Conference on Tuesday, February 25, 2020 at 1PM (EST) in New York. The Cowen and Company Annual Health [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[10],"tags":[],"class_list":["post-1957","post","type-post","status-publish","format-standard","hentry","category-press-release"],"acf":{"external_link":"","presentation":"","meta_short_title":"BridgeBio And Eidos To Present At Investor Conferences","meta_description":"","meta_share_image":false,"people":false},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BridgeBio\/Eidos To Present At Investor Conferences | BridgeBio<\/title>\n<meta name=\"description\" content=\"BridgeBio and Eidos announced they have agreed to acquire all of the outstanding common stock of Eidos it does not already own. Learn more today!\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-and-eidos-therapeutics-to-present-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio\/Eidos To Present At Investor Conferences | BridgeBio\" \/>\n<meta property=\"og:description\" content=\"BridgeBio and Eidos announced they have agreed to acquire all of the outstanding common stock of Eidos it does not already own. Learn more today!\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-and-eidos-therapeutics-to-present-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:published_time\" content=\"2020-02-22T00:25:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-22T20:01:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Brandon Keller\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Brandon Keller\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-and-eidos-therapeutics-to-present-at-upcoming-investor-conferences\/\",\"url\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-and-eidos-therapeutics-to-present-at-upcoming-investor-conferences\/\",\"name\":\"BridgeBio\/Eidos To Present At Investor Conferences | BridgeBio\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2020-02-22T00:25:02+00:00\",\"dateModified\":\"2022-06-22T20:01:03+00:00\",\"author\":{\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/6cd954001e2cec42c2e8290f7c570325\"},\"description\":\"BridgeBio and Eidos announced they have agreed to acquire all of the outstanding common stock of Eidos it does not already own. Learn more today!\",\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-and-eidos-therapeutics-to-present-at-upcoming-investor-conferences\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-and-eidos-therapeutics-to-present-at-upcoming-investor-conferences\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-and-eidos-therapeutics-to-present-at-upcoming-investor-conferences\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/6cd954001e2cec42c2e8290f7c570325\",\"name\":\"Brandon Keller\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3f5f406075c438807a4d70dccadd771a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3f5f406075c438807a4d70dccadd771a?s=96&d=mm&r=g\",\"caption\":\"Brandon Keller\"},\"url\":\"https:\/\/bridgebio.com\/author\/bkeller\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BridgeBio\/Eidos To Present At Investor Conferences | BridgeBio","description":"BridgeBio and Eidos announced they have agreed to acquire all of the outstanding common stock of Eidos it does not already own. Learn more today!","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-and-eidos-therapeutics-to-present-at-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"BridgeBio\/Eidos To Present At Investor Conferences | BridgeBio","og_description":"BridgeBio and Eidos announced they have agreed to acquire all of the outstanding common stock of Eidos it does not already own. Learn more today!","og_url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-and-eidos-therapeutics-to-present-at-upcoming-investor-conferences\/","og_site_name":"BridgeBio","article_published_time":"2020-02-22T00:25:02+00:00","article_modified_time":"2022-06-22T20:01:03+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"author":"Brandon Keller","twitter_card":"summary_large_image","twitter_creator":"@BridgeBioPharma","twitter_site":"@BridgeBioPharma","twitter_misc":{"Written by":"Brandon Keller","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-and-eidos-therapeutics-to-present-at-upcoming-investor-conferences\/","url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-and-eidos-therapeutics-to-present-at-upcoming-investor-conferences\/","name":"BridgeBio\/Eidos To Present At Investor Conferences | BridgeBio","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2020-02-22T00:25:02+00:00","dateModified":"2022-06-22T20:01:03+00:00","author":{"@id":"https:\/\/bridgebio.com\/#\/schema\/person\/6cd954001e2cec42c2e8290f7c570325"},"description":"BridgeBio and Eidos announced they have agreed to acquire all of the outstanding common stock of Eidos it does not already own. Learn more today!","breadcrumb":{"@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-and-eidos-therapeutics-to-present-at-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/news\/bridgebio-pharma-and-eidos-therapeutics-to-present-at-upcoming-investor-conferences\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-and-eidos-therapeutics-to-present-at-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/6cd954001e2cec42c2e8290f7c570325","name":"Brandon Keller","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3f5f406075c438807a4d70dccadd771a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3f5f406075c438807a4d70dccadd771a?s=96&d=mm&r=g","caption":"Brandon Keller"},"url":"https:\/\/bridgebio.com\/author\/bkeller\/"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/1957"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=1957"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/1957\/revisions"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=1957"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/categories?post=1957"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/tags?post=1957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}